Roche launched next-generation portfolio of SARS-CoV-2 rapid antigen tests
On Oct. 11, 2022, Roche announced the launch of its next-generation portfolio SARS-CoV-2 rapid antigen tests (“2.0”) for…
-
-
Intranasal COVID-19 vaccine candidate’s clinical data highlighted need for further development of nasal spray vaccines
On Oct. 11, 2022, researchers from the University of Oxford have reported new findings from a Phase 1…
-
Novavax and SK bioscience filed post approval change application in South Korea for Nuvaxovid COVID-19 vaccine as booster in adults
On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to…
-
Switzerland’s Federal Office of Public Health recommended Novavax Nuvaxovid COVID-19 vaccine as booster in adults
On Oct. 10, 2022, Novavax announced that Switzerland’s Federal Office of Public Health had recommended Nuvaxovid (NVX-CoV2373) as…
-
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster received Health Canada authorization for individuals 12 years of age and older
On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada had authorized COMIRNATY Original & Omicron BA.4/BA.5…
-
Japanese vaccine database Created to assess Vaccine Effectiveness and adverse events
On Oct. 6, 2022, researchers in Japan released a study that described the development and application of the…
-
Merck and Ridgeback Biotherapeutics provided update on new clinical and non-clinical studies of LAGEVRIO (molnupiravir)
On Oct. 6, 2022, Merck and Ridgeback Biotherapeutics issued the following announcement regarding data from two real-world evidence…
-
Washington University in St. Louis COVID-19 nasal vaccine technology licensed to Ocugen
On Oct. 4, 2022, Washington University in St. Louis announced it had licensed the rights to develop, manufacture…
-
EMA accepted Moderna’s conditional Marketing Authorization filing for omicron BA.4/BA.5 targeting bivalent COVID-19 vaccine
On Sept. 29, 2022, Moderna announced that the European Medicines Agency (EMA) had accepted a variation for the…
-
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5-adapted bivalent vaccine Booster in children 5 through 11 years of age
On Sept. 28, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
-
Study confirmed link between COVID-19 vaccination and temporary increase in menstrual cycle length
On Sept. 27, 2022, the National Institutes of Health (NIH) announced that a large international study had confirmed…
-
Novavax made one million doses of Nuvaxovid available for use in the United Kingdom
On Sept. 27, 2022, Novavax announced that an initial one million doses of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine were…
-
Pfizer to supply global fund up to 6 million PAXLOVID treatment courses for low-and-middle-income countries
On Supt. 22, 2022, Pfizer announced an agreement to supply up to six million treatment courses of its…
-
Novavax Nuvaxovid COVID-19 vaccine received expanded EUA in Taiwan for use in adolescents aged 12 through 17
On Sept. 16, 2022, Novavax announced that the Taiwan Food and Drug Administration had granted expanded emergency use…
-
Novavax Nuvaxovid COVID-19 vaccine became available in Israel for individuals aged 12 and older
On Sept. 16, 2022, Novavax announced that the Israel Ministry of Health has granted an import and use…
-
WHO expanded recommendation for Veklury (Remdesivir) to patients with severe disease in update to COVID-19 guideline
On Sept. 15, 2022, Gilead Sciences announced updates to the World Health Organization’s (WHO) Therapeutics and COVID-19: living…
-
NIH-funded team developed method to identify future SARS-CoV-2 mutations that could affect rapid antigen test performance
On Sept. 15, 2022, the National Institutes of Health (NIH) announced that a research team funded by the…
-
Novavax and Serum Institute of India announced full product registration in South Africa of Novavax COVID-19 vaccine
On Sept. 13, 2022, Novavax and Serum Institute of India, the world’s largest vaccine manufacturer by volume, announced…
-
Swissmedic authorized Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as booster in adults
On Sept. 2, 2022, Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, had expanded its temporary…
-
World Health Organization approved SK bioscience as supplier of Novavax Nuvaxovid COVID-19 vaccine
On Sept. 2, 2022, Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, had expanded its temporary…
-
Novavax Nuvaxovid COVID-19 vaccine recommended by CHMP for expanded conditional Marketing Authorization in EU as booster for adults
On Sept. 1, 2022, Novavax announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional marketing…
-
$838 Million neurosciences center broke ground in Connecticut
On Aug. 31, 2022, the Yale New Haven Hospital broke ground on the $838 million, 505,000 square foot…
-
Novavax Nuvaxovid COVID-19 vaccine granted expanded conditional marketing authorization in UK for use in adolescents aged 12 through 17
On Aug. 26, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
Pfizer and BioNTech completed submission to EMA for Omicron BA.4/BA.5 adapted bivalent vaccine
On Aug. 26, 2022, Pfizer and BioNTech announced they had completed a submission to the European Medicines Agency…
-
Pfizer and BioNTech announced updated COVID-19 vaccine data supporting efficacy in children 6 months through 4 years of age
On Aug. 23, 2022, Pfizer and BioNTech announced updated efficacy results from a Phase 2/3 trial evaluating a…
-
Pfizer and BioNTech submitted application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine
On Aug. 22, 2022, Pfizer and BioNTech announced they had completed a submission to the U.S. Food and…
-
Moderna completed application to U.S. FDA for EUA of omicron-targeting bivalent Covid-19 booster vaccine
On Aug. 22, 2022, Moderna announced it has applied for an U.S. Food and Drug Administration (FDA) emergency…
-
Moderna announced supplying 12 million doses of Omicron-containing bivalent COVID-19 booster vaccines to Government of Canada
On Aug. 23, 2022, Moderna announced they will supply 12 million doses of its COVID-19 shot adapted to…
-
U.S. FDA granted EUA for Novavax COVID-19 vaccine, adjuvanted for adolescents Aged 12 through 17
On Aug. 19, 2022, Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received expanded emergency use…
-
Novavax Nuvaxovid COVID-19 vaccine granted expanded provisional approval in New Zealand for adolescents aged 12 through 17
On Aug. 18, 2022, Novavax announced that New Zealand’s Medsafe had granted expanded provisional approval for Nuvaxovid (NVX-CoV2373)…
